Description
Founded in 1999, Novo Holdings is a venture capital firm based in Copenhagen, Denmark. The firm prefers to invest in biotech, pharma, medtech, bioindustrials, and services.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Engimmune Therapeutics | 03-May-2022 | Seed Round | 000.00 | Drug Discovery | Generating Revenue | 0ø0000 0ø0000 00000000 00.0 |
0000.00 | 29-Mar-2022 | 00000 00000 | 0000 | Other Healthcare Technology Systems | Generating Revenue | 0000 00000 00 |
000000 | 28-Mar-2022 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - Phase 1 | 000000 0000000000000 |
00000000 | 16-Mar-2022 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 000000 0ø00000 |
00000000 | 28-Feb-2022 | 00000 00000 | 0000 | Building Products | Generating Revenue | 000000 00000 00.0 |
00000 000000000000 | 22-Feb-2022 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | |
000 00000000 | 18-Feb-2022 | 0000000000 | Pharmaceuticals | Profitable | 00000000 0000 | |
00000000 000000000 | 16-Feb-2022 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 0000000 000000 00.0 |
NMD Pharma | 15-Feb-2022 | Later Stage VC | 000.00 | Drug Discovery | Generating Revenue | 000000 0ø00000 |
Vestaron | 09-Feb-2022 | Later Stage VC | 0000 | Agricultural Chemicals | Generating Revenue | 000000 0000000000000 |
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Arcellx | 16-Jun-2022 | Public Investment 2nd Offering | 00000 |
0000000 | 09-Jun-2022 | 000000000000000000 | 00000 |
000000000 00000000 | 31-May-2022 | 000000000000000000 | 00000 |
000000 00000000000 | 28-Apr-2022 | 000000 0000000000 | 00000 |
0000000 0000000000 | 25-Feb-2022 | 000000000000000000 | 000 |
0000000 | 04-Feb-2022 | 000 | 00000 |
0000000 000000 | 13-Dec-2021 | 000000000000000000 | 00000 |
00 0000000 | 05-Nov-2021 | 000 | 00000 |
Minerva (Therapeutic Devices) | 26-Oct-2021 | IPO | 0000 |
Exscientia | 01-Oct-2021 | IPO | 00000 |
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Kasim Kutay | Chief Executive Officer | 0 | 0 | 0 | San Francisco, CA |
Christoffer Søderberg | Managing Partner & Head of Principal Investments. | 0 | 0 | 0 | Copenhagen, Denmark |
Morten Beck Jørgensen | Managing Partner, Financial Investments | 0 | 0 | 0 | Copenhagen, Denmark |
Søren Moller Ph.D | Managing Partner, Novo Seeds | 00 | 0 | 0 | Copenhagen, Denmark |
Scott Beardsley | Managing Partner, Novo Ventures (US) | San Francisco, CA |
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
RA Capital Management | 11 | 00 |
![]() |
![]() |
|
OrbiMed | 0 | 0 | 00 |
![]() |
![]() |
Rock Springs Capital | 0 | 0 |
![]() |
![]() |
|
Vivo Capital | 0 | 0 | 0 |
![]() |
![]() |
Citadel Enterprise Americas | 0 | 0 |
![]() |
![]() |